|
|
Archive - Agenda:
Registration
Information
Continue to day two
| 08.00 |
Registration and Coffee |
| 09.00 |
Assay Development & Cell Based
Screening
Chaired by Dr. Paul Bernasconi
Applying Physiologically Relevant Signaling to Ion Channel Lead Generation.
Dr. Paul Bernasconi , Director,
Amphora Discovery Corporation
The How, Why and When of Protein Kinase
Screening
Dr. David Hayes, Scientific
Development Manager, Upstate Group
Improved BRET2 as a Compound Screening Assay
Dr. Anders Heding, Head of Molecular
Screening, 7TM Pharma
Ultra-High-Throughput Protease Inhibitor Screening
Dr. Jim Inglese, Senior Research Fellow, Merck
Phosphatases: from Screening to Preclinical
Dr. Dominique Perrin, Group Leader -
Biochemical Pharmacology, Serono
Pharmaceutical Research Institute
|
| 12.10 |
Lunch & Exhibition
|
| 12.40 |
Vendor
Presentations |
| 14.00 |
ADMET
Screening
Integrated
Approaches to Non-Clinical Safety Testing
Dr. Frank Bonner, Consultant,
Focus Biosciences Ltd
The Importance of Physicochemical Properties in the Assessment
of New Drugs
Dr. John
Comer, Technical Director, Sirius Analytical
Accelerated
Screening for the Potential of a Drug Candidate to Cause Adverse Reactions
Prof. Peter O'Brien, Faculty of Pharmacy,
Toronto University
Application of New
Proprietary Models and Transcriptional Profiling in Lead Compound Selection
Dr. Simon Plummer, Senior Scientist, CXR Biosciences
|
| 16.50 |
Poster
Presentations |
| 16.50 |
Wine
Reception in Exhibition
Sponsored by Caliper Life Sciences |
Registration
Information
|
|
|